Application of ALC1 to preparation of leukaemia drug resistance reversing agent and as drug-resistant leukaemia diagnosing reagent

A leukemia and drug resistance technology, applied in pharmaceutical formulations, gene therapy, genetic material components, etc., can solve problems such as the inability to effectively predict chemotherapeutic agent tolerance, and achieve significant effects, high efficiency, and improved sensitivity.
CN102526762BActive Publication Date: 2013-03-27广州医学院
2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
广州医学院
Publication Date
2013-03-27

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the field of leukaemia drug resistance and discloses application of an ALC1 inhibitor to preparation of a leukaemia drug resistance reversing agent and application of an ALC1 gene to preparation of a drug-resistant leukaemia diagnosing reagent. The expression of the ALC1 gene in a peripheral blood sample or a bone marrow sample of a patient is detected; and based on a characteristic that the high expression of the gene is related to the increase of the resistance of a cell to chemotherapeutic medicines, sensitive chemotherapeutic agents can be screened. The invention further discloses an application of the ALC1 gene to preparation of the leukaemia drug resistance reversing agent. By inhibiting the expression of the ALC1 gene, the drug resistance of the cell can be reversed, the sensitivity of a leukemia cell to the medicine can be improved, and the cell inhibiting effects and the apoptosis promoting effects of various chemotherapeutic medicines can be improved, so that the ALC1 inhibitor can be applied to the preparation of acute and chronic leukaemia multidrug resistance reversing agents and a new method for treating the drug-resistant leukaemia is provided.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of leukemia drug resistance, in particular to the application of ALC1 gene in the diagnosis of drug-resistant leukemia, the screening of sensitive chemotherapeutic agents and the preparation of leukemia drug resistance reversal agent. Background technique

[0002] Leukemia is a clonal disease of hematopoietic stem cells, which is characterized by uncontrolled proliferation and differentiation disorder of leukemia cells in clones, blocked apoptosis, and stagnation at different stages of cell development. The treatment of leukemia is mainly chemotherapy, targeted therapy and bone marrow transplantation. Bone marrow transplantation is limited by many factors such as donor source and patient age. Therefore, only a small number of patients can actually receive bone marrow transplantation, and most patients need chemotherapy. and targeted drug therapy. In the process of drug treatment of leukemia, combined chemotherapy has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More